New study data: JANUVIA (sitagliptin) Nov 22, 2008
There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JANUVIA or any other anti-diabetic drug. Expanding clinical development program for sitagliptin family. (EurekAlert!)
Hypertension develops early, silently, in African-American men Nov 17, 2008
"Although having a similar cardiovascular risk factor profile as young white men, diffuse macrovascular and microvascular dysfunction is present at a young age in apparently healthy African American men," the authors wrote. "Values seen are comparable to values often reported in older individuals or individuals with more advanced hypertensive disease," they said. (EurekAlert!)
Long-Term Follow-up after Control of Blood Pressure in Diabetes Oct 10, 2008
Background Post-trial monitoring of patients in the United Kingdom Prospective Diabetes Study (UKPDS) examined whether risk reductions for microvascular and macrovascular disease, achieved with the use of improved blood-pressure control during the trial, would be sustained. Methods Among 5102 UKPDS patients with newly diagnosed type 2 diabetes mellitus, we randomly assigned, over a 4-year period beginning in 1987, 1148 patients with hypertension to tight or less-tight blood-pressure control... (New England Journal of Medicine)
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes Oct 10, 2008
We conducted post-trial monitoring to determine whether this improved glucose control persisted and whether such therapy had a long-term effect on macrovascular outcomes. Methods Of 5102 patients with newly diagnosed type 2 diabetes, 4209 were randomly assigned to receive either conventional therapy (dietary restriction) or intensive therapy (either sulfonylurea or insulin or, in overweight patients, metformin) for glucose control. (New England Journal of Medicine)
Tight Blood Sugar Control Helps Diabetics Long-Term Sep 12, 2008
"This suggests that early glucose-lowering treatment brings greater benefits than starting later in the course of the disease, reducing not only micro but also macrovascular risks.". Wang agreed. (MEDLINEplus)
Amylins Byetta: physicians remain skeptical of drugs real-world benefit Aug 22, 2008
In light of the FDAs new draft guidance, Singh said there will be tougher standards on new diabetes drugs and their effects on cardiovascular and other micro and macrovascular hard endpoints. You have to prove additional improvements, and Im not sure we know that Byetta has those improvements, he added. (FT.com -- Markets)
Studies Differ on Benefits of Aggressive Blood Sugar Control Jun 10, 2008
"There were no clear effects on macrovascular complications such as heart attack or stroke," Patel said. "Most importantly, using the strategy we employed for intensive glucose control, there was no increased risk of death.". (MEDLINEplus)
Backpack Straps Can Decrease Blood Flow In The Shoulder And Arm, And May Result In Loss of Fine Motor Control Apr 9, 2008
The researchers concluded that backpack loads of just 26 pounds decrease upper extremity macrovascular and microvascular blood flows, and may result in a loss of fine motor control and increased fatigue. According to Timothy Neuschwander, MD, the first author of the study and a physician, We surmise that the mechanism of diminished blood flow is likely due to strap compression of the axillary vein. (Science Daily)
Grape Skin Compound Fights The Complications Of Diabetes Mar 21, 2008
The elevated levels of glucose that circulate in the blood of patients with diabetes causes micro- and macrovascular complications by damaging mitochondria, the tiny power plants within cells responsible for generating energy. When they are damaged they can leak electrons and make highly damaging 'free radicals. (Science Daily)
ADVANCE diabetes trial results confirm no evidence of safety risk Feb 29, 2008
Reference: ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Heller S, Liu L, Mancia G, Mogensen C, Pan C, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. (EurekAlert!)
Major International Diabetes Study Does Not Confirm Increased Risk Of Death Reported By US Trial Feb 16, 2008
Journal reference: ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Heller S, Liu L, Mancia G, Mogensen C, Pan C, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. (Science Daily)
Diabetes dilemma: older people with diabetes face a heavy burden from co-existing health conditions Nov 14, 2007
Meanwhile, 81 percent had at least one of the macrovascular problems that are aggravated or triggered in part by diabetes, including high blood pressure, coronary artery disease, a history of stroke or mini-stroke, or heart failure. The researchers also looked at three unrelated diseases. (EurekAlert!)
The management of diabetes in IndigenousAustralians in the primary care setting Oct 25, 2007
Indigenous Australians with diabetes had high rates of micro- and macrovascular disease ... When compared to non-Indigenous patients, Indigenous patients were more likely to have established macrovascular disease (adjusted Odds ratio 2 ... This cross-sectional study confirms Aboriginal ethnicity as a powerful risk factor for microvascular and macrovascular disease, which practitioners should use to identify candidates for intensive multifactorial intervention. (BioMed Central)
Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association Sep 12, 2007
This meta-analysis adds important information to the body of evidence regarding ACTOS and macrovascular ischemic events, and further documents the consistency of data from prospective studies, to meta-analysis, to observational studies. Critical in this body of data is PROactive (PROspective PioglitAzone Clinical Trial In MacroVascular Events), a trial of patients with type 2 diabetes who are at high risk for cardiovascular events ... These data show no increase in mortality or total... (EurekAlert! -- Business News)
Kidneys, eyes and feet are prime targets of the diabetes epidemic Sep 2, 2007
Doctors group diabetes complications into two major categories: microsvascular (affecting small blood vessels) and macrovascular (affecting larger ones) ... Macrovascular complications include heart disease, heart failure and strokes. (Pittsburgh Post-Gazette, PA)
Vitamin B1 Deficiency Key To Vascular Problems For Diabetic Patients, Study Suggests Aug 12, 2007
Diabetes is increasing in incidence in the UK and elsewhere and one of the most significant health problems associated with the condition are vascular complications: microvascular complications, such as damage to the kidney, retina and nerves in arms and legs; and macrovascular complications, such as heart disease and stroke ... The researchers found that the decreased availability of thiamine in vascular cells in diabetes was linked to a marker of microvascular and macrovascular complications. (Science Daily)
Takeda Responds to the FDA Advisory Committee Recommendation Jul 31, 2007
"Critical in this body of data is the PROactive (PROspective PioglitAzone Clinical Trial In MacroVascular Events) study, since the only scientific way to determine a medication's safety is a prospective, long-term trial." About the PROactive Study PROactive was a prospective, randomized, placebo-controlled outcomes trial. The PROactive study included 5,238 patients with type 2 diabetes and a history of macrovascular disease, who were force titrated up to 45 mg daily of either ACTOS or placebo... (PR Newswire)
LCA Announces Sedona Diabetes Wellness Program Jul 4, 2007
Diabetes is a disease in which the body does not properly produce or does not properly use insulin, leading to abnormally high blood sugar which causes microvascular and macrovascular damage. The fifth leading cause of death, it has become epidemic in America, affecting more than 20 million people. (PR Newswire)
